Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03409614
Title Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals

lung non-squamous non-small cell carcinoma

lung squamous cell carcinoma


Cemiplimab + Ipilimumab


Age Groups: senior | adult
Covered Countries USA | ITA | FRA | AUT

Additional content available in CKB BOOST